1-4 of 4
David M Kofler, MD
Close
Sort by
Journal Articles

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).

David M Kofler, MD, Barbara B Gawlik, MD, Thomas Elter, MD, Athos Gianella-Borradori, MD, Clemens M Wendtner, MD, Michael Hallek, MD
Journal: Blood
Blood (2009) 114 (22): 2373.
https://doi.org/10.1182/blood.V114.22.2373.2373
Published: 2009
Journal Articles

CD28 Costimulation of Effector T Cells During An Anti-Tumor Attack Sustains Its Repression by Regulatory T Cells Which Can Be Overcome by Preventing Lck Activation.

David M Kofler, MD, Markus Chmielewski, PhD, Tobias Riet, Andreas Hombach, MD, Michael Hallek, MD, Clemens M Wendtner, MD, Hinrich Abken, MD
Journal: Blood
Blood (2009) 114 (22): 3569.
https://doi.org/10.1182/blood.V114.22.3569.3569
Published: 2009
Journal Articles

Impact of Regulatory T Cells on Antigen Specific T Cell Response Using Recombinant Chimeric T Cell Receptors In Vivo.

David M. Kofler, MD, Markus Chmielewski, Heike Koehler, Tobias Riet, Patrick Schmidt, Gunter Rappl, Andreas Hombach, MD, Michael Hallek, MD, Clemens M. Wendtner, MD, Hinrich Abken, MD
Journal: Blood
Blood (2006) 108 (11): 5475.
https://doi.org/10.1182/blood.V108.11.5475.5475
Published: 2006
Journal Articles

High Incidence of Translocations in CLL: A New Prognostic Marker for Infavorable Survival Outcome.

Christine Mayr, MD, David M. Kofler, MD, Raymund Buhmann, MD, John Strehl, MD, Raymonde Busch, Michael Hallek, MD, Clemens-Martin Wendtner, MD
Journal: Blood
Blood (2004) 104 (11): 17.
https://doi.org/10.1182/blood.V104.11.17.17
Published: 2004